|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In vitro and in vivo analyses indicated that the products of PROSC, SH2D4A, and SORBS3 have tumor-suppressive activities, along with the known tumor suppressor gene DLC1.
|
22202459 |
2012 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The deleted in liver cancer-1 (DLC-1) gene that encodes a Rho GTPase-activating protein with tumor suppressor function is located on chromosome 8p21-22, a region frequently deleted in prostate carcinomas.
|
16533763 |
2006 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 as a potential tumor suppressor.
|
27604574 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC-1 (deleted in liver cancer-1) is a potential tumor suppressor gene, which is inactive in liver carcinogenesis.
|
18288400 |
2008 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Taken together, our results suggest that DLC-1 might be an NPC-related tumor suppressor gene affected by aberrant promoter methylation and gene deletion.
|
16680376 |
2006 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our findings suggest that DLC-1 may play an important role in lymphoma by acting as a bona fide new tumor suppressor gene.
|
20882354 |
2011 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma.
|
29785050 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Regardless of the epigenetic mechanism of DLC1 inactivation, SAHA treatment of DLC1-transduced cells had a synergistic inhibitory effect on tumor cell proliferation and tumorigenesis in both cell lines.
|
20198346 |
2010 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The aim of this study was to evaluate whether DLC-1, a newly identified tumor-suppressor gene on chromosome 8p22, is involved in the tumorigenesis of MBs and the histologically similar SPNETs.
|
15712180 |
2005 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC-1 (deleted in liver cancer-1) is a tumor suppressor gene for hepatocellular carcinoma and other cancers.
|
17292327 |
2007 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC1 was also identified as an estrogen-induced tumor suppressor in the normal mammary gland with decreased expression in breast cancer.
|
31110002 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.
|
16951145 |
2006 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A recent study in Genes & Development by Xue and colleagues (1439-1444) now provides in vivo evidence that DLC1, a negative regulator of Rho, is a tumor suppressor gene deleted almost as frequently as p53 in common cancers such as breast, colon, and lung.
|
18593873 |
2008 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Since DLC‑1 is a candidate tumor suppressor gene, we sought to determine whether DLC‑1 expression is associated with cell proliferation in colon cancer cell lines.
|
23783552 |
2013 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC1 appears to be a major TSG implicated in the pathogenesis of these tumors, and should be further tested as a molecular biomarker in patients with these cancers.
|
16862168 |
2007 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC-1 is a multi-domain protein that includes a Rho GTPase activating protein (RhoGAP) domain which has been hypothesized to be the basis of its tumor suppressive actions.
|
17932950 |
2008 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC-1 inhibits cell growth and invasion in human colon cancer, functioning as a tumor-suppressor gene, possibly through the regulation of the Wnt/β-catenin signaling pathway.
|
24604602 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data suggest that DLC1 might act as a CHD-associated gene in addition to its role as a tumor suppressor in cancer.
|
24587289 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC-1 (deleted in liver cancer 1) is a candidate tumor suppressor gene for hepatocellular carcinoma and other cancers.
|
12034501 |
2002 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, introduction of the DLC-1 cDNA abolished the in vivo tumorigenicity in nude mice, suggesting that the DLC-1 gene plays a role in breast cancer by acting as a bona fide tumor suppressor gene.
|
12545165 |
2003 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The delineation of the gene structure allows mutation analysis of DLC1 in other tumour types for which it remains a candidate tumour suppressor gene based on its location and homology to rhoGAP.
|
10649492 |
2000 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC-1 may be a tumor suppressor gene in liver cancer as well as in other cancers.
|
9605766 |
1998 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A tumor suppressor Deleted in Liver Cancer 1 (DLC1) has been reported to be down-regulated or even silenced in several kinds of cancer including breast cancer.
|
27830358 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Importantly, when fused to the tat protein-transduction sequence and subsequently introduced into cells, the C2 peptides potently promoted the RhoGAP function in DLC1, leading to decreased RhoA activation and reduced tumor cell growth in soft agar and migration in response to growth factor stimulation.
|
31806702 |
2020 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Tripathi investigates how the tumor suppressor DLC1 is regulated by oncogenic kinases.
|
31515239 |
2019 |